A growing network of psychiatry clinics, research sites and therapeutic retreats specialized in psychedelic medicine

Message: CLIENT FEATURE: Novamind (NM: CSE) (NVMDF: OTC) Leaders In Psychedelic Medicine

Novamind Partners with Merck for New Treatment-Resistant Depression Trial

  • Wholly-owned subsidiary, Cedar Clinical Research selected as a key research site for a clinical trial focused on treatment-resistant depression by Merck & Co. a world-leading pharmaceutical company
  • Phase II study will assess the efficacy and safety of a new Merck drug for treatment-resistant depression (TRD), a mental health condition that affects approximately 30% of people who suffer from major depressive disorder

Why Novamind?

  • Building the infrastructure required for a regulated psychedelics industry
  • Rapidly expanding a network of outpatient mental health clinics and research sites
  • Provides ketamine-assisted psychotherapy and Spravato™ (esketamine) treatments;
    • Ketamine treatment volume grew 90% from 2019 to 2020
    • During the same period, total Spravato™ treatments rose 400%
  • Positioned to facilitate MDMA and psilocybin therapy post-FDA approval
  • Specializing in psychedelic-assisted treatment protocols
  • Building centers of excellence for future approved psychedelic treatments
  • Biopharma partnerships with Johnson & Johnson (Janssen Spravato trials) and Merck for New Treatment-Resistant Depression Trial
  • $1.29 million in fiscal second quarter revenue
  • Strong insider ownership (32.3%)

Watch Our Recent Interview


Novamind is focused on 3 pillars:



Hub On AGORACOM / Corporate Profile

FULL DISCLOSURE: Novamind is an advertising client of AGORA Internet Relations Corp.

New Message
Please login to post a reply